Clearside Biomedical Inc (CLSD)
1.075
+0.04
(+3.86%)
USD |
NASDAQ |
Nov 05, 16:00
1.075
0.00 (0.00%)
After-Hours: 20:00
Clearside Biomedical Research and Development Expense (Annual): 20.85M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 20.85M |
| December 31, 2022 | 19.63M |
| December 31, 2021 | 18.54M |
| December 31, 2020 | 15.07M |
| December 31, 2019 | 15.66M |
| December 31, 2018 | 68.29M |
| Date | Value |
|---|---|
| December 31, 2017 | 49.05M |
| December 31, 2016 | 19.46M |
| December 31, 2015 | 10.76M |
| December 31, 2014 | 6.692M |
| December 31, 2013 | 5.045M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
15.07M
Minimum
2020
20.85M
Maximum
2023
17.95M
Average
18.54M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Viking Therapeutics Inc | 63.81M |
| Arcus Biosciences Inc | 340.00M |
| Crinetics Pharmaceuticals Inc | 168.53M |
| Biomea Fusion Inc | 102.55M |
| NovaBay Pharmaceuticals Inc | 0.068M |